Continuous Glucose Monitoring in Kidney Transplant Recipients with Diabetes, Pre-diabetes and Without Diabetes

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes. The primary objective is to analyse differences in mean sensor glucose between these three groups. CGMs are applied to participants within 72 hours after kidney transplantation, with a total of 54 participants divided equally across the three groups (18 in each). Secondary objectives include assessing additional glucose profile indices, adherence to relevant guidelines, changes in HbA1c, the impact of immunosuppression and steroid dosage, and beta cell function.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Written informed consent obtained before CGM application

• Male or female; age: ≥18 years

• Kidney transplantation

Locations
Other Locations
Denmark
Rigshospitalet
RECRUITING
Copenhagen
Contact Information
Primary
Ida S Voss, MD
Ida.voss@regionh.dk
+4535457063
Time Frame
Start Date: 2024-11-12
Estimated Completion Date: 2026-01-01
Participants
Target number of participants: 54
Treatments
Diabetes
Diabetes group defined as type 2 diabetes, type 1 diabetes, receiving glucose-lowering therapy, FPG ≥ 7 mmol/l, HbA1c ≥ 48mmol/l or non-fasting plasma glucose ≥11.1 mmol/l
No diabetes
No diabetes defined as HbA1c \<42mmol/mol or FPG\<6.1 mmol/L
Prediabetes
Prediabetes group defined as HbA1c 42-47 mmol/mol or FPG 6.1-6.9 mmol/L
Related Therapeutic Areas
Sponsors
Leads: Bo Feldt-Rasmussen

This content was sourced from clinicaltrials.gov